55
Participants
Start Date
December 14, 2023
Primary Completion Date
July 1, 2025
Study Completion Date
November 1, 2025
therapeutic program including intermittent drug intake and multimodal rehabilitation program
"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
RECRUITING
CHU Clemront-Ferrand, Clermont-Ferrand
Plateforme d'Investigation Clinique, INSERM CIC1405, CHU de Clermont-Ferrand, France
UNKNOWN
Fondation Apicil
OTHER
Médecine Physique et Réadaptation, CHU de Clermont-Ferrand, France
UNKNOWN
Médecine du Sport et Explorations Fonctionnelles, CHU de Clermont-Ferrand, France
UNKNOWN
Rhumatologie, CHU de Clermont-Ferrand, France
UNKNOWN
Direction de la Recherche Clinique et des Innovations, CHU de Clermont-Ferrand, France
UNKNOWN
SARL BOUCHARENC, Saint-Chély d'Apcher, France
UNKNOWN
"Inserm U1107 Neuro-Dol , Clermont-Ferrand, France"
UNKNOWN
Université Clermont-Auvergne, France
UNKNOWN
University Hospital, Clermont-Ferrand
OTHER